Unknown

Dataset Information

0

A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin.


ABSTRACT: We are in the midst of the global pandemic. Though acute respiratory coronavirus (SARS-COV2) that leads to COVID-19 infects people of all ages, severe symptoms and mortality occur disproportionately in older adults. Geroscience interventions that target biological aging could decrease risk across multiple age-related diseases and improve outcomes in response to infectious disease. This offers hope for a new host-directed therapeutic approach that could (i) improve outcomes following exposure or shorten treatment regimens; (ii) reduce the chronic pathology associated with the infectious disease and subsequent comorbidity, frailty, and disability; and (iii) promote development of immunological memory that protects against relapse or improves response to vaccination. We review the possibility of this approach by examining available evidence in metformin: a generic drug with a proven safety record that will be used in a large-scale multicenter clinical trial. Though rigorous translational research and clinical trials are needed to test this empirically, metformin may improve host immune defenses and confer protection against long-term health consequences of infectious disease, age-related chronic diseases, and geriatric syndromes.

SUBMITTER: Justice JN 

PROVIDER: S-EPMC7479299 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5991909 | biostudies-literature
| S-EPMC9550513 | biostudies-literature
| S-EPMC7856630 | biostudies-literature
| S-EPMC6379255 | biostudies-other
| S-EPMC8190215 | biostudies-literature
| S-EPMC5610818 | biostudies-other
| S-EPMC10434535 | biostudies-literature
| S-EPMC10461194 | biostudies-literature
| S-EPMC8007926 | biostudies-literature
| S-EPMC5109899 | biostudies-literature